Germantown, Maryland-based Senseonics has begun its first human study of Freedom, an experimental continuous glucose monitoring (CGM) system designed to send glucose readings directly from an implanted sensor to a smartphone. The October 26 announcement marks a new clinical development step for the Maryland medical technology company as it works toward a glucose monitor that would not require a device worn on the skin.
Moving Beyond the Wearable Transmitter
Freedom builds on the sensing technology used in Senseonics’ commercially available Eversense 365 system, but adds an integrated battery and Bluetooth communication inside the implant. Unlike Eversense 365, which requires a removable external transmitter, Freedom is designed to communicate directly with a mobile device. That could reduce the number of components patients manage during daily glucose monitoring. The distinction is still a development goal: Freedom is investigational, and its intended year-long operation without an on-body component has not yet been established in clinical use.
Early Testing Focuses on Safety and Connectivity
The first-in-human study is an early feasibility evaluation of device safety and function, including whether Bluetooth signals can reliably travel from the implanted sensor to a phone. In preclinical work completed during the second quarter of 2026, Senseonics tested antenna designs and implant locations. Its preferred configuration achieved 100% communication success within a specified target distance across approximately seven weeks and more than 18,500 communication data points.
Germantown’s Growing Role in Diabetes Device Innovation
The milestone extends a series of developments at the Maryland-headquartered company. Senseonics already markets Eversense 365, an FDA-cleared implantable CGM designed for up to one year of glucose monitoring, and in September announced a partnership with Beta Bionics to work toward integrating that existing sensor with the iLet Bionic Pancreas. Freedom is a separate investigational product and should not be confused with the cleared Eversense 365 system or the proposed pump integration. The company’s Germantown headquarters gives the research milestone a direct connection to Maryland’s medical device ecosystem.
